India has more than 100 million people living with diabetes, putting a large population at risk of complications that include vision loss.
Researchers at the University of Michigan are studying a naturally occurring protein that could eventually offer another way to protect eyesight. They found that the protein, called Norrin, helped reduce blood vessel leakage in the retina, inflammation and nerve cell death. The treatment also preserved vision, including when it was administered after vision had begun to deteriorate.
The findings, published in the journal Diabetes, suggest a different approach to treating diabetic eye disease. While existing treatments primarily block a protein that contributes to blood vessel leakage, David Antonetti, professor of ophthalmology and visual sciences at U-M’s Kellogg Eye Center, and collaborators are investigating whether Norrin can help restore the protective barrier that diabetes damages.
The distinction is important, he said, because current treatments do not work equally well for everyone.
Existing therapies target vascular endothelial growth factor, or VEGF, a protein that contributes to abnormal blood vessel growth and leakage in the retina. Drugs that block VEGF have improved treatment for diabetic eye disease, but some patients do not receive the full benefit.
“The big thing is that these therapies block VEGF from causing more damage,” Antonetti said. “And what we’re looking at here is a factor that’s involved in normally creating the proper vascular environment in the retina.”
The retina, the light-sensitive tissue at the back of the eye, relies on a protective barrier in its blood vessels to regulate what enters the surrounding tissue. Diabetes can damage this barrier, allowing fluid to leak into the retina. The resulting swelling, known as diabetic macular edema, can affect central vision. Norrin helps form and maintain this barrier. Antonetti and colleagues wanted to find out whether replacing the protein could help repair the damage caused by diabetes.
Their experiments showed that Norrin levels declined in diabetic rats. Supplying the protein helped restore the barrier, reduced inflammation and protected retinal nerve cells from damage.
“So, this factor is down, and we’re replacing it,” Antonetti said. “There’s real hope that since it’s a restoring factor and we’re losing it … that we can restore the barrier.”
Why the research matters for India
According to the ICMR-INDIAB nationwide study published in The Lancet Diabetes & Endocrinology in 2023, an estimated 101 million people in India were living with diabetes. The study found that 11% of Indian adults had diabetes, while another 15% had prediabetes.
Although not everyone with diabetes develops sight-threatening eye disease, the number of people affected makes finding better ways to prevent and treat diabetic retinopathy especially important. Antonetti cautioned that there is no evidence a Norrin-based treatment would be more effective in India than elsewhere. Its potential lies in providing another option for people who do not get enough benefit from existing treatments.
“The hope is that this can maybe be effective when anti-VEGFs are not,” he said.
Whether the approach will help patients who respond poorly to anti-VEGF drugs remains to be determined. But the possibility of another treatment could be particularly meaningful in countries such as India, where diabetes affects millions of people.
From laboratory research to clinical trials
Antonetti said the research into Norrin has also contributed to efforts to develop treatments that work through the same biological pathway. He described collaborations aimed at developing a therapy based on these findings and discussed an investigational drug that has advanced into clinical trials. Rather than supplying Norrin directly, the drug activates the pathway through which Norrin helps maintain the blood-retinal barrier.
Antonetti said a clinical trial had found the investigational treatment to be non-inferior to ranibizumab, an established anti-VEGF drug. That means it met the trial’s standard for performing comparably to the existing treatment. He also discussed Merck’s involvement in further clinical testing.
Researchers have not yet established whether this approach will work better for patients who respond poorly to anti-VEGF drugs or whether combining the two treatments could provide additional benefits.
Another challenge is how the treatment would reach patients. Antonetti explained that the investigational drug still requires injections into the eye, much like existing therapies. Longer-lasting delivery methods might eventually reduce the need for frequent injections, but those possibilities require further research.
For India, where millions of people with diabetes face the risk of vision loss, the findings offer hope for expanding treatment options. If future studies confirm the benefits of targeting the Norrin pathway, the approach could provide another way to preserve vision, particularly for patients who do not fully benefit from current therapies.








